特别关注｜PD-1/PD-L1在肝细胞癌治疗中的应用(11)

[5]YAU T, HSU C, KIM TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552. DOI: 10.1016/j.jhep.2019.05.014
[6]KUDO M, MATILLA A, SANTORO A, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status[J]. J Clin Oncol, 2019, 37(4 Suppl): 327.
[7]KAMBHAMPATI S, BAUER KE, BRACCI PM, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series[J]. Cancer, 2019, 125(18): 3234-3241. DOI: 10.1002/cncr.32206
[8]YAU T, PARK JW, FINN RS, et al. CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30(Suppl 5): v874-v875.
[9]SUN YK. Interpretation of CSCO guidelines for the diagnosis and treatment of primary liver cancer: Systemic treatment[J/CD]. Electronic J Liver Tumor, 2018, 5(3): 11-14. (in Chinese)